摘要
目的:探讨加味逍遥丸对CYP2C19活性的影响,为临床指导联合用药提供依据。方法:将20名受试者按照CYP2C19*2基因型进行分类,野生型纯合子(WW)及突变型纯合子(MM)各10名。以奥美拉唑作为CYP2C19的探针药,研究服用加味逍遥丸对人体内代谢酶CYP2C19活性的影响。采用pyrosequencing测序法对CYP2C19进行基因分型,采用HPLC-MS/MS法测定探针药及其代谢产物的血药浓度。结果:连续服用14 d加味逍遥丸。以AUC0-12为指标,评价CYP2C19代谢酶的活性。受试者用药前CYP2C19代谢酶活性为5.7±1.6,服用加味逍遥丸后CYP2C19代谢酶活性为6.0±1.7。用药后代谢酶的活性升高,用药前后比较采用配对t检验,差异没有统计学意义。结论:服用加味逍遥丸对CYP2C19代谢酶活性没有明显影响。
AIM: To investigate the effect of Modified Xiaoyao pill on CYP2C19,and provide foundation for clinical drug using. METHODS: Twenty volunteers were divided into two groups according to CYP2C19*2 gene type,ten for WW gene type and ten for MM gene type.Omeprazole used as probe drug of CYP2C19,the effect of Modified Xiaoyao pill on the activity of CYP2C19 were investigated.Genetic classification was fulfilled by pyrosequencing method,and the blood concentration of probe drug and its metabolic product were determined by HPLC-MS/MS.RESULTS:The volunteers took Modified Xiaoyao pill for two weeks,AUC0-12 was used as the standard of the activity of CYP2C19.The activity value was 5.7±1.6 before drug and 6.0±1.7 after drug using.So the activity of CYP2C19 was increased after drug using,t-test was used for comparison,there was no remarkable difference between the data.CONCLUSION: Modified Xiaoyao pill has no obvious affection on the activity of CYP2C19.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2011年第4期407-411,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics